Analysis Of The Prognostic Factors In Endometrial Carcinoma

Objective: To analyze retrospectively the clinical information of167patients with Endometrial Carcinoma in the Fourth Hospital of Hebei MedicalUniversity. To evaluate the related risk factors affecting prognosis and therelationship between various clinicopathologic factors.Methods: The clinicopathologic factors and outcomes of167patientswith endometrial carcinoma underwent primary surgical treatment andconfirmed by pathology from Jan2007to Jul2009in the Fourth Hospital ofHebei Medical University were reviewed and analyzed. analyze the prognosticfactors of the endometrial carcinoma.SPSS13.0software package was used. Survival rates were calculatedusing Kaplan-Meier method. The prognostic factors were evaluated byunivariate and multivariate analysis. Univariate analysis and the comparisonbetween the survival rates was estimated by log-rank test. Multiple regressionanalysis were assessed by Cox proportional hazards model. Enumeration datawere compared with χ~2test. A statistically significant difference was indicatedby P<0.05.Results：1The1-year，2-year，3-year overall survival rates after surgery of167cases with endometrial carcinoma were96%，93%，91%，respectively.2This research was single factor analysis on15may and endometrialcancer prognosis associated risk factors. In the analysis of the ten risk factors,age(χ~2=4.303, P＜0.05), menopausl state(χ~2=5.243, P＜0.05), histologicaltype(χ~2=6.705， P＜0.05), tumor grade(χ~2=20.720， P＜0.05), operation-pathological stage(χ~2=44.582, P＜0.05), depth of myometrial invasion(χ~2=22.302, P＜0.05), cervical invasion(χ~2=4.443, P＜0.05), ovarianmetastasis(χ~2=11.416, P＜0.05), lymphovascular space involvement(χ~2=12.464, P＜0.05), lymph node metastasis, ER(χ~2=5.613， P＜0.05), PR(χ~2=5.891, P＜0.05), treatment modality(χ~2=9.881, P＜0.05) and adjuvanttherapy(χ~2=15.258, P＜0.05),can significantly influence endometrial cancer5-year survival of patients. Pregnancy (χ~2=0.047, P＞0.05)on the survival ofpatients with endometrial cancer had no significant effect.3Multivariate analysis revealed that age, histological type, operation-pathological stage, depth of myometrial invasion and lymphovascular spaceinvolvement, affect the survival of patients with endometrial cancer.4Multivariate analysis revealed that age, histological type, operation-pathological stage, depth of myometrial invasion and lymphovascular spaceinvolvement, were associated significantly with overall-survival.5Comparison of various clinicopathologic factors related to lymph nodemetastasis, there were significant differences in histological type, tumorgrade，depth of myometrial invasion，cervical invasion, ovarian metastasis andlymphovascular space involvement(P<0.05).Conclusions:13-year survival rate of endometrial cancer patients is more than90%,this shows endometrial cancer patients with a good prognosis.2Univariate analysis revealed that age, menopausl state, histologicaltype, tumor grade, operation-pathological stage, depth of myometrialinvasion， cervical invasion, ovarian metastasis, lymphovascular spaceinvolvement, lymph node metastasis, ER, PR, treatment modality andadjuvant therapy were significantly associated with the overall-survival.3Multivariate analysis revealed that age, histological type, operation-pathological stage, depth of myometrial invasion and lymphovascular spaceinvolvement,were associated significantly with overall-survival.4Comparison of various clinicopathologic factors related to lymph nodemetastasis,there were significant differences in histological type, tumor grade，depth of myometrial invasion，cervical invasion, ovarian metastasis andlymphovascular space involvement. The incidence of lymph node metastasisincreased in patients with special pathological type, poorly differentiated tumor, deep myometrium invasion, cervical involvement, ovarian metastasis,lymphovascular space involvemen.5The treatment of patients with endometrial cancer should be strictlyassess the patient’s prognosis, the implementation of individualized treatment,choose the best treatment options to improve the prognosis, and improve thequality of life.